1 Q2 2023 Financial Results Presentation August 1, 2023 rıgel. Forward Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1955 ("PSLRA") relating to, among other things, the potential and market opportunity of olutasidenib as therapeutics for R/R AML and other conditions; the potential and market opportunity for fostamatinib as therapeutics for chronic ITP, COVID-19 and other conditions; the regulatory approval and c ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 0-29889 Rigel Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 94-3248524 (Sta ...

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Q1 2023 Earnings Conference Call May 2, 2023 4:30 PM ET Company Participants Ray Furey - EVP, General Counsel and Corporate Secretary. Raul Rodriguez - President and CEO Dave Santos - EVP and Chief Commercial Officer Dean Schorno - EVP and Chief Financial Officer Conference Call Participants Eun Yang - Jefferies Carly Kenselaar - Citi Allison Bratzel - Piper Sandler Kalpit Patel - B. Riley Operator Greetings, and welcome to the Rigel Pharmaceuticals Financial Confer ...

Q1 2023 Financial Results Presentation 1 May 2, 2023 Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1955 ("PSLRA") relating to, among other things, the potential and market opportunity of olutasidenib as therapeutics for R/R AML and other conditions; the potential and market opportunity for fostamatinib as therapeutics for chronic ITP, COVID-19 and other conditions; the regulatory approval and commerciali ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 0-29889 Rigel Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 94-3248524 (St ...

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Q4 2022 Earnings Conference Call March 7, 2023 4:30 PM ET Company Participants Ray Furey - EVP, General Counsel and Corporate Secretary. Raul Rodriguez - President and CEO Dave Santos - EVP and Chief Commercial Officer Wolfgang Dummer - EVP and Chief Medical Officer Dean Schorno - EVP and Chief Financial Officer Conference Call Participants Carly Kenselaar - Citi Eun Yang - Jefferies Do Kim - Piper Sandler Kristen Kluska - Cantor Fitzgerald Gary Nachman - BMO Capita ...

| --- | --- | --- | |--------------------------------|-------|-------| | | | | | | | | | Q4 & YE 2022 Financial Results | | | | Presentation March 7, 2023 | | | | | | | 1 Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1955 ("PSLRA") relating to, among other things, the potential and market opportunity of olutasidenib as therapeutics for R/R AML and other conditions; the potential and market opportunity fo ...

Table of Contents kr UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 000-29889 RIGEL PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 94-3248524 (State or other jurisdiction of (IRS ...

Corporate Presentation 1 January 2023 Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1955 ("PSLRA") relating to, among other things, expected commercial and financial results for the fourth quarter and fiscal year ended December 31, 2022; Rigel's ability to earn and receive milestone payments; expectations related to the potential and market opportunity of olutasidenib as therapeutics for R/R AML and othe ...

| --- | --- | --- | |------------------------------|-------|-------| | | | | | | | | | Q3 2022 Financial Results | | | | Presentation November 3,2022 | | | | | | | 1 Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1955 ("PSLRA") relating to, among other things, the development and commercialization of olutasidenib; the timing of launch of olutasidenib; the progress of the RIPK1 inhibitor program in collabo ...